Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Acquisitions & Divestments (2023)

Historic Change in Acquisitions & Divestments for Monte Rosa Therapeutics (GLUE) over the last 1 years, with Q1 2023 value amounting to $45.6 million.

  • Monte Rosa Therapeutics' Change in Acquisitions & Divestments changed N/A to $45.6 million in Q1 2023 from the same period last year, while for Dec 2023 it was $45.6 million, marking a year-over-year change of. This contributed to the annual value of $45.6 million for FY2023, which is N/A changed from last year.
  • Monte Rosa Therapeutics' Change in Acquisitions & Divestments amounted to $45.6 million in Q1 2023.
  • Over the past 5 years, Monte Rosa Therapeutics' Change in Acquisitions & Divestments peaked at $45.6 million during Q1 2023, and registered a low of $45.6 million during Q1 2023.